Patriot Financial Group Insurance Agency LLC Reduces Position in Pfizer Inc. $PFE

Patriot Financial Group Insurance Agency LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 85.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,207 shares of the biopharmaceutical company’s stock after selling 90,653 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Pfizer were worth $368,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Vanguard Group Inc. grew its stake in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the last quarter. State Street Corp raised its stake in shares of Pfizer by 0.5% in the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares during the period. Morgan Stanley boosted its position in Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares during the last quarter. Finally, Norges Bank purchased a new stake in Pfizer in the fourth quarter valued at approximately $1,830,986,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PFE. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Pfizer in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.28.

Pfizer Stock Down 0.1%

Pfizer stock opened at $26.77 on Friday. The business’s 50-day moving average price is $25.12 and its 200 day moving average price is $26.20. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market cap of $152.60 billion, a price-to-earnings ratio of 35.23 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the company posted $0.78 earnings per share. Pfizer’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.